WO2002100843A1 - Composes phenoxazines, preparations les contenant et leurs utilisations medicinales - Google Patents

Composes phenoxazines, preparations les contenant et leurs utilisations medicinales Download PDF

Info

Publication number
WO2002100843A1
WO2002100843A1 PCT/CN2001/000968 CN0100968W WO02100843A1 WO 2002100843 A1 WO2002100843 A1 WO 2002100843A1 CN 0100968 W CN0100968 W CN 0100968W WO 02100843 A1 WO02100843 A1 WO 02100843A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
medicinal uses
phenoxazine compounds
phenoxazine
compounds
Prior art date
Application number
PCT/CN2001/000968
Other languages
English (en)
Chinese (zh)
Inventor
Jianqing Lu
Original Assignee
Jianqing Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jianqing Lu filed Critical Jianqing Lu
Priority to PCT/CN2001/000968 priority Critical patent/WO2002100843A1/fr
Priority to CN01801106A priority patent/CN1366519A/zh
Publication of WO2002100843A1 publication Critical patent/WO2002100843A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

L'invention concerne des composés phénoxazines de formule (I), ainsi que les sels, esters, amides et promédicaments de ceux-ci, acceptables au plan pharmaceutique, les préparations pharmaceutiques les contenant, et l'utilisation de médicaments pour l'inhibition de la coagulation de la protéine amylacée. Les définitions de R1, R2 et R dans la formule sont décrites dans la spécification.
PCT/CN2001/000968 2001-06-13 2001-06-13 Composes phenoxazines, preparations les contenant et leurs utilisations medicinales WO2002100843A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2001/000968 WO2002100843A1 (fr) 2001-06-13 2001-06-13 Composes phenoxazines, preparations les contenant et leurs utilisations medicinales
CN01801106A CN1366519A (zh) 2001-06-13 2001-06-13 吩噁嗪类化合物及其药物组合物和其医药应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000968 WO2002100843A1 (fr) 2001-06-13 2001-06-13 Composes phenoxazines, preparations les contenant et leurs utilisations medicinales

Publications (1)

Publication Number Publication Date
WO2002100843A1 true WO2002100843A1 (fr) 2002-12-19

Family

ID=4574812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000968 WO2002100843A1 (fr) 2001-06-13 2001-06-13 Composes phenoxazines, preparations les contenant et leurs utilisations medicinales

Country Status (2)

Country Link
CN (1) CN1366519A (fr)
WO (1) WO2002100843A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118580A3 (fr) * 2004-05-12 2006-08-03 Us Gov Health & Human Serv Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique
GB2433071A (en) * 2005-12-05 2007-06-13 Kontrakt Technology Ltd Organic acids comprising planar conjugated heterocyclic molecular system, & photoelectric layer thereof with rodlike supramolecules for use in solar cell

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819423B (zh) * 2014-02-13 2015-04-15 江苏傲伦达科技实业股份有限公司 一种合成n–芳基–吩噁嗪类化合物的方法
CN109512824B (zh) * 2018-11-14 2021-07-16 吉林大学 刃天青在作为牛胰岛素淀粉样纤维抑制剂方面的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156347A2 (fr) * 1984-03-29 1985-10-02 Roche Diagnostics GmbH Glycosides de dérivés de la résofurine, leur méthode de préparation et emploi pour la détermination de l'activité de la glycosidase
CN1086825A (zh) * 1992-08-31 1994-05-18 弗·哈夫曼-拉罗切有限公司 三环和四环化合物
US5498542A (en) * 1994-09-29 1996-03-12 Bayer Corporation Electrode mediators for regeneration of NADH and NADPH

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156347A2 (fr) * 1984-03-29 1985-10-02 Roche Diagnostics GmbH Glycosides de dérivés de la résofurine, leur méthode de préparation et emploi pour la détermination de l'activité de la glycosidase
CN1086825A (zh) * 1992-08-31 1994-05-18 弗·哈夫曼-拉罗切有限公司 三环和四环化合物
US5498542A (en) * 1994-09-29 1996-03-12 Bayer Corporation Electrode mediators for regeneration of NADH and NADPH

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118580A3 (fr) * 2004-05-12 2006-08-03 Us Gov Health & Human Serv Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique
GB2433071A (en) * 2005-12-05 2007-06-13 Kontrakt Technology Ltd Organic acids comprising planar conjugated heterocyclic molecular system, & photoelectric layer thereof with rodlike supramolecules for use in solar cell

Also Published As

Publication number Publication date
CN1366519A (zh) 2002-08-28

Similar Documents

Publication Publication Date Title
WO2004074266A8 (fr) 1,2,4-triazines inhibant le vih
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
WO2005075471A3 (fr) Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
WO2005037798A3 (fr) Nouveaux composés
WO2003087050A3 (fr) Sel de perindopril et les compositions pharmaceutiques qui le contiennent
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
WO2003018059A3 (fr) Preparations combinatoires de derives de propanolamine substitues par aryle avec d'autres principes actifs et leur utilisation
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
WO2003050067A3 (fr) Analogues de la vitamine d
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002100843A1 (fr) Composes phenoxazines, preparations les contenant et leurs utilisations medicinales
DE69813263T2 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
AU2001266019A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
WO2004072037A8 (fr) Derives de 2,3'-bipyridines servant d'inhibiteurs de cox-2 selectifs
ATE286893T1 (de) 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 01801106.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP